A comparative analysis of risk stratification tools in SSc-associated pulmonary arterial hypertension: a EUSTAR analysis
Authors:
- Hilde Jenssen BjørkekjærHBHilde Jenssen Bjørkekjær
- Cosimo BruniCBCosimo Bruni
- Kaspar BrochKBKaspar Broch
- Cathrine BrunborgCBCathrine Brunborg
- Patricia E CarreiraPCPatricia E Carreira
- Paolo AiròPAPaolo Airò
- Carmen Pilar Simeón-AznarCSCarmen Pilar Simeón-Aznar
- Marie-Elise TruchetetMTMarie-Elise Truchetet
- Alessandro GiolloAGAlessandro Giollo
- Alexandra Balbir-GurmanABAlexandra Balbir-Gurman
- Mickael MartinMMMickael Martin
- Christopher P DentonCDChristopher P Denton
Open Access
- 29 January 2025
- journal article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (6) , 3643-3656
Abstract
Objectives: The 2022 European Society of Cardiology and European Respiratory Society (ESC/ERS) guidelines for pulmonary arterial hypertension (PAH) recommend risk stratification to optimize management. However, the performance of generic PAH risk stratification tools in patients with SSc-associated PAH remains unclear. Our objective was to identify the most accurate approach for risk stratification at SSc-PAH diagnosis. Methods: In this multicentre, international cohort study from the European Scleroderma Trials and Research (EUSTAR) group database, we screened 11 risk stratification tools upon SSc-PAH diagnosis. We compared the performance of the three top-ranked tools to predict mortality with the ESC/ERS three-strata model, the currently recommended tool for baseline risk assessment. We also assessed the impact of incorporating SSc-specific characteristics into the tools. Kaplan–Meier analyses and Cox regression with area under the ROC curve (AUC) were conducted. Results: The ESC/ERS three-strata model had a lower ability to predict mortality than the ESC/ERS four-strata model, ‘SPAHR updated’ and ‘REVEAL Lite 2’. The ESC/ERS four-strata model divided ‘intermediate-risk’ patients into two groups with significantly different long-term survival rates and is the easiest applicable tool. Incorporating SSc-specific characteristics did not significantly improve the predictive ability of any model, but a low diffusing capacity of the lung for carbon monoxide (DLCO) was an independent predictor of mortality. Conclusion: Considering its ability to predict mortality, risk segregation capabilities and clinical applicability, this study provides a rationale for using the simplified ESC/ERS four-strata model at SSc-PAH diagnosis as an alternative to the comprehensive ESC/ERS three-strata model. We propose considering DLCO as an individual prognostic marker in SSc-PAH.Keywords
Funding Information
- Scleroderma Research Foundation
- Gruppo Italiano Lotta alla Sclerodermia
- Novartis Foundation for Medical-biological Research
- NIHR
- Welcome Trust
- Bayer, Boehringer Ingelheim, Janssen and Medscape (US8247389, EP2331143)
- Chair of the Executive Committee for the FOREUM Foundation
- Swiss Clinical Quality Management in Rheumatic Diseases
- Swiss Academy of Medical Sciences
This publication has 47 references indexed in Scilit:
- Selexipag in patients with pulmonary arterial hypertension associated with connective tissue disease (PAH‐CTD): Real‐world experience from EXPOSUREPulmonary Circulation, 2024
- Macitentan in Pulmonary Arterial Hypertension Associated with Connective Tissue Disease (CTD-PAH): Real-World Evidence from the Combined OPUS/OrPHeUS DatasetCardiology and Therapy, 2024
- Treatment of pulmonary arterial hypertension in patients with connective tissue diseases: a systematic review and meta-analysisInternal and Emergency Medicine, 2024
- Long‐Term Outcomes in Patients With Connective Tissue Disease–Associated Pulmonary Arterial Hypertension in the Modern Treatment Era: Meta‐Analyses of Randomized, Controlled Trials and Observational RegistriesArthritis & Rheumatology, 2021
- The prevalence and incidence rate of pulmonary arterial hypertension in systemic sclerosis: Systematic review and meta-analysisAutoimmunity Reviews, 2021
- Predicting Survival in Patients With Pulmonary Arterial HypertensionChest, 2019
- Idiopathic and Systemic Sclerosis-Associated Pulmonary Arterial HypertensionChest, 2017
- Current Approaches to the Treatment of Systemic-Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)Current Rheumatology Reports, 2016
- Survival and Predictors of Mortality in Systemic Sclerosis‐Associated Pulmonary Arterial Hypertension: Outcomes From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma RegistryArthritis Care & Research, 2013
- Survival and Prognostic Factors in Systemic Sclerosis–Associated Pulmonary Hypertension: A Systematic Review and Meta‐AnalysisArthritis & Rheumatism, 2013